Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1408 - Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen

    Primary Author / Presenter(s)

  • XG

    Xutao Guo

    Department of Hematology, Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong, China (People's Republic)

    • Co-Author(s)

  • YZ

    Yunxia Zhang

    Department of Hematology, Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong, China (People's Republic)

  • XW

    Xiaolei Wei

    Department of Hematology, Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong, China (People's Republic)

  • YW

    Yongqiang Wei

    Department of Hematology, Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong, China (People's Republic)

  • HL

    Haohao Lei

    Department of Hematology, Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong, China (People's Republic)

  • NS

    Ning Su

    Department of Hematology, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
    GUANGZHOU, Guangdong, China (People's Republic)

  • RF

    Ru Feng, MD

    Department of Hematology, Nanfang Hospital, The Southern Medical University
    Guangzhou, United States